PARIS, Jan 27 (Reuters) - Healthcare companies Sanofi
and Regeneron announced on Friday that the
European Union's medicines regulator had given a new stage of
approval for their Dupixent product to treat children as young
as six months old with severe atopic dermatitis.The European Commission is expected to announce a final
decision on the Dupixent application in the coming months, while
in June 2022 Dupixent had already been approved by the U.S. Food
and Drug Administration (FDA) regulator for children in this age
group.
(Reporting by Sudip Kar-Gupta; Editing by Jacqueline Wong)